Healthcare Industry Weekly Report 20240805: 48 Financing Deals Globally, 16 in China

【Targeted Radiopharmaceuticals】Bivision Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel targeted radiopharmaceuticals to address significant unmet medical needs. Bivision Pharmaceuticals possesses three major technology platforms: targeted ligand screening, radiopharmaceutical conjugation, and clinical translation of drugs, with several drug pipelines advancing simultaneously. It has a diversified R&D pipeline spanning different stages of the drug discovery and development process. Its lead candidate, JH02, is a lutetium-177 labeled small molecule ligand targeting prostate-specific membrane antigen (PSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). JH02 has received approval from the FDA and CDE and is currently in Phase I/II clinical trials.

【Investor】Joaquin Investment, Joaquin Avenue, Tigermed, Gaorong Capital, Licheng Capital

【Targeted RNA Small Molecule Drugs】ReviR Therapeutics, founded in 2021, is a biotechnology company that combines AI technology to develop small-molecule drugs targeting RNA. By leveraging cutting-edge technology and the AI-powered drug discovery platform VoyageR, the company aims to advance more effective and safer targeted RNA therapies to address unmet clinical needs in cancer and genetic diseases. This round of financing will primarily be used to further develop the VoyageR platform and continue advancing preclinical and clinical stage development across multiple pipelines related to neurological disorders such as Huntington's disease (HD), Charcot-Marie-Tooth disease (CMT), and amyotrophic lateral sclerosis (ALS).

【Investor】Lone Pine Capital, CDH Investments, 5Y Capital, APlus Investment Development, Bivision Pharmaceuticals, CMT Research Foundation

【Antitumor Probiotic Drugs】Shenzhen Shengbao Biotechnology Co., Ltd. was founded in 2023, with its headquarters located in Shenzhen, China. The company is committed to the research and development of innovative live bacterial drugs, utilizing genetic circuits and precise control of gene and payload expression to meet the therapeutic needs of various types of diseases. Shenzhen Shengbao Biotechnology currently prioritizes the development of live bacterial drugs for solid tumor treatments. With unique mechanistic insights and advanced quantitative synthetic biology technologies, the company aims to develop anti-tumor live bacterial drugs that are safe, efficient, broad-spectrum, targeted, and non-invasive.

【Investor】Boehringer Ingelheim Venture Fund, Dart NeuroScience Ventures, Fosun Health Capital, Legend Capital

【Tumor Immunotherapy】LTZ Therapeutics is a leading global biotechnology company that develops innovative immunotherapies for cancer and other complex diseases with significant unmet clinical needs, systematically enhancing patient clinical outcomes. The company’s international team is located in Shenzhen, China; Palo Alto, California, USA; and Heidelberg, Germany. Based on reverse translational science and emerging tumor microenvironment biology, LTZ Therapeutics is committed to developing next-generation immunotherapies that not only overcome drug resistance and recurrence but also enhance anti-tumor immunity.

【Investor】LAV Partners, Qiming Venture Partners, K2VC, Shunwei Capital, Hillhouse Ventures

【Nanobody】Shanghai Luoqi Biomedical Technology Co., Ltd., located in the Shanghai International Medical Park in Pudong New Area, Shanghai, is committed to the research and development of innovative nanobody drugs. Since its establishment in October 2017, Luoqi Biotech has built a research and production base covering more than 2,500 square meters as well as a camel breeding base. Meanwhile, Luoqi Biotech has independently established five core technology platforms based on nanobodies: a rapid nanobody screening platform, a Pichia pastoris CMC process development platform, an inhalable macromolecular drug research and development platform, a long-acting nanobody platform, and a bispecific nanobody platform. Each of these platforms has unique industry advantages, enabling the rapid screening of nanobody drugs with pharmaceutical activity and their swift industrialization. Based on a comprehensive R&D system, Luoqi Biotech has screened multiple antibody new drugs with pharmaceutical activity, filed over 30 domestic and international invention patents, and applied for 5 PCT invention patents.

【Investor】Qiming Venture Partners, Huangpu Pharmaceutical Fund, Shengdi Private Equity

【Cancer, Kidney Disease Drugs】ZhiKang Hongyi was founded in December 2017. The company is committed to discovering, developing, and commercializing novel or highly differentiated drug candidates (with no modality restrictions) to treat diseases with significant unmet medical needs, particularly cancer and kidney diseases. Through internal research, an open innovation platform, and collaborations, ZhiKang Hongyi has established a pipeline of more than 10 innovative projects, including small molecule antibodies, monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs).

【Investors】Binhu Industrial Group, Wuxi Jintou, WuXi Biologics

【Neurodegenerative Disease Gene Therapy】Shenji Changhua Biotechnology Co., Ltd. was established at the end of 2021 as a biopharmaceutical enterprise focused on gene therapy for neurological diseases. Its core pipeline originates from over a decade of fundamental research成果转化 in the field of neuroscience conducted by Professor Yi-Chang Jia's laboratory at the School of Medicine, Tsinghua University. The team primarily focuses on ALS (Amyotrophic Lateral Sclerosis), stroke, Parkinson's disease (PD), Alzheimer's disease (AD), and other neurological disorders, particularly neurodegenerative diseases.

【Investor】Zhongbo Power, Chuanhua Capital, Sanmei Investment

【Microendoscope】Jingwei Shida Medical Technology (Wuhan) Co., Ltd. is a national high-tech enterprise specializing in the research, development, and production of advanced precision optical biopsy technologies. Based on its proprietary core hardware and manufacturing processes, and integrating advanced imaging algorithms for clinical applications, the company provides optical biopsy products capable of real-time in vivo cellular observation. It is committed to eliminating uncertainties in disease diagnosis (especially cancer diagnosis) through optical biopsy technology, thereby improving the detection rate of early-stage cancers and significantly enhancing patient treatment outcomes. Focused on delivering clinically valuable advanced technologies for the early precise diagnosis and treatment of tumors, its product portfolio spans three major technological fields: minimally invasive diagnostic and therapeutic access technologies for early-stage tumors, real-time non-invasive visual biopsy technologies, and minimally invasive treatment technologies for early-stage tumors.

【Investor】Huisheng Fund, Su High-Tech Investment, Kaixian Capital, Su High-Tech Financial Control, Changfei Fund

【Endoscope】Riverside Medical is a global supplier providing cost-effective disposable endoscopes, with a product development plan covering urology, gynecology, otolaryngology, respiratory medicine, general surgery, and more. To date, the company has initiated the development of over 130 new products, of which more than 10 have obtained Class II registration certificates, and two products have obtained Class III registration certificates. The company has an international team of expert technicians and consistently adheres to multi-dimensional innovation and independent research and development.

【Investor】Tianxin Emerging Industries Fund, Guangzhou Industrial Investment Group, SuXin Yihe, Highland Capital, Tongying Venture Capital, Guangzhou Yuexiu Industrial Fund, Yuanhe Origin

【Injection and Puncture Instruments】Herci is committed to the reliable design, development, and mass production services of complete drug delivery devices, an industry that is still largely vacant in China's pharmaceutical sector. In 2018, Herci’s next-generation Cartridge Injection Pen, after four years of research and development, was released with 11 injection pen patents, five of which are invention patents. It is currently the only domestically produced commercial product in China that can replace imported products, and it possesses independent and complete intellectual property rights. In 2020, Herci’s newly developed fully automatic pencil-type injector met all design requirements during validation tests, filling another product gap for domestically produced pencil-type injectors.

【Investor】Jianchuang Medical Growth Fund, Fuzhe Equity, Lishui Fuchu Fund, Herui Venture Capital

【Medical Polymer Materials】GUYUAN Medical, established in 2005, is a leading comprehensive solutions provider for medical devices and medical consumables in China. The company has built an end-to-end solution covering precision mold design and manufacturing, R&D of medical polymer materials, to lean production of medical consumables and structural components of medical devices. With absolutely leading technical strength and market position in areas such as in vitro diagnostics, medical imaging, and life support, it has become a core supplier for top domestic medical industry companies including Mindray Medical, New Industries Biomedical, YHLO Biotech, and BGI Group.

【Investor】Guiyang Venture Capital

【Wearable Devices】Future Wearable Technology Co., Ltd. is a company focused on the development, design, and manufacturing of wearable devices and products in the healthcare field, established in 2007. It has been committed to researching, developing, designing, and producing high-quality wearable massagers, providing consumers with smart technology and excellent service experiences. Its product line includes neck massagers, eye massagers, and body massagers, among others.

【Investor】Morgan Stanley PE Asia

【Synthetic Biology】Yanwei Technology, relying on patented technology from Tsinghua University, is committed to the green bio-manufacturing of specialty chemicals for applications in agriculture, oilfields, daily chemicals, pharmaceuticals, and other fields. Its business covers high anti-adversity biocatalysts, nano and single-atom metal catalysts based on biological templates, and high value-added specialty chemicals. The technical level of some products is among the industry leaders. In addition to having complete and uniquely advantageous R&D capabilities in synthetic biotechnology and green chemical technology, Yanwei Technology also possesses solid professional expertise and practical experience in the engineering implementation and commercialization of new products. Two categories of products are already ready for mass production and are currently undergoing application testing in collaboration with leading customers across various fields.

【Investor】Yizhuang Guotou, Jinxin Capital, Sequoia Capital China Fund, FreesFund Fengrui Capital, Kangyu Capital, CDH VGC